Skip to content

Morbidity in Open Versus Minimally Invasive Esophagectomy

Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03035071
Acronym
MIOMIE
Enrollment
26
Registered
2017-01-27
Start date
2010-05-01
Completion date
2016-04-18
Last updated
2017-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer

Keywords

Minimal-invasive esophagectomy, Esophageal resection, Hybrid esophagectomy

Brief summary

The MIOMIE trial is a prospective randomized controlled study comparing open and laparoscopic gastric tube formation in Ivor Lewis esophagectomy. Aim of this trial was to compare the minimally invasive approach with the standard open procedure regarding morbidity and mortality.

Detailed description

Esophageal resection is still associated with considerable morbidity and mortality. Standardized preoperative efforts could increase the outcome of these patients. While early reports of medical pioneers focused particularly on safety and feasibility, more recent studies showed that implementation of minimally invasive esophagectomy (MIE) was widely accepted. Since first reports of MIE, different techniques and adjustments have been discussed. A recent publication of a large prospective trial in Phase II showed the safety of a total minimally invasive approach (video assisted thoracoscopic surgery (VATS) and laparoscopy). Surgical technique however is still a subject of debate and the level of evidence remains still low. Proving feasibility does not warrant a paradigm shift, as experience is an important factor for safety and patient benefit. The aim of this study was to evaluate morbidity and mortality of open esophagectomy (OE) versus hybrid-MIE in a randomized controlled setting. Prior to surgery patients will be randomized either the minimally invasive surgery group (laparoscopic gastric tube formation and thoracotomy) or the the open surgery group (open gastric tube formation with an open laparotomy approach). Randomizing tool is the randomizer of the medical university of vienna. (link is attached below)

Interventions

In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.

in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.

Sponsors

Austrian Society Of Surgical Oncology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* adenocarcinoma of the esophagus and the esophagogastric junction in (Siewert) type I and II position * esophageal squamous cell cancer * patients, who require esophageal resection due to above mentioned diagnosis * patients, who gave their informed consent

Exclusion criteria

* individuals who did not meet the inclusion criteria were excluded from the study. * patients with tumor localization in the upper third of the esophagus and requiring cervical resection were excluded. * patients, presenting other than AC or ESCC or showed contraindication for laparoscopy (history of large abdominal surgery or signs of hostile abdomen) * patients with a history or presence of any other malignancy, except carcinoma in situ or basalioma

Design outcomes

Primary

MeasureTime frameDescription
morbidity30 daysanastomotic leakage, gastric conduit necrosis and/or pneumonia
mortality30 days

Secondary

MeasureTime frameDescription
ICU stay90 dayslength of stay at the intensive care unit (ICU)
hospital stay90 dayslength of stay at the hospital
overall survival5 yearslong term overall survival
relapse free survival5 yearslong term relapse free survival

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026